Unifying heterogeneous expression data to predict targets for CAR-T cell therapy
Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression and is tumor specific. This strategy has been s...
Guardado en:
Autores principales: | Patrick Schreiner, Mireya Paulina Velasquez, Stephen Gottschalk, Jinghui Zhang, Yiping Fan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf7f740860484a71a617907389cbe23f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
por: Shakeri S., et al.
Publicado: (2021) -
Impact of Perioperative Absolute Neutrophil Count on Central Line-Associated Bloodstream Infection in Children With Acute Lymphoblastic and Myeloid Leukemia
por: Illya Martynov, et al.
Publicado: (2021) -
Ajuste de intensidad para el trasplante hematopoyético alogénico en leucemia aguda
por: Sarmiento M,Mauricio, et al.
Publicado: (2016) -
Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Varvara Maiorova, et al.
Publicado: (2021) -
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz MJ, et al.
Publicado: (2020)